Go Pro
TSE:CTX

Crescita Therapeutics Q4 2025 Earnings Report

Crescita Therapeutics logo
C$0.79 0.00 (0.00%)
As of 06/4/2026

Crescita Therapeutics EPS Results

Actual EPS
-C$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Crescita Therapeutics Revenue Results

Actual Revenue
$5.96 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Crescita Therapeutics Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Tuesday, March 31, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Crescita Therapeutics Earnings Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Crescita Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Crescita Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescita Therapeutics and other key companies, straight to your email.

About Crescita Therapeutics

Crescita Therapeutics (TSE:CTX) Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.

View Crescita Therapeutics Profile